100% stake in French es company proposed

Today, the shares of Fred (300049) unveiled the reason for the suspension last week, that is, the company is planning to acquire France Echosens SA Company (hereinafter referred to as "es Company") 100% stake in the matter. On the midday of January 10, the shares of the company issued a notice of suspension of "major matters" and the shares were suspended in the afternoon. Today's announcement shows that the company is currently planning on the acquisition of ES company 100% stake in related matters.　　After the company's application, the company's stock has continued to suspend business since 9:30 January 17, 2011, pending the above related matters confirmed after the license. The bulletin showed that the ES company mainly produces ultrasonic diagnostic equipment (FibroScan) for liver elasticity testing, and the ultrasonic diagnostic instrument is the first noninvasive instant detection device to diagnose and monitor the value of liver hardness by quantification.　　At present, the shares of the company's subsidiaries Inner Mongolia Rui Pharmaceutical Co., Ltd. is Fibroscan products in China (excluding Hong Kong and Taiwan), the exclusive distributor. The prospectus of the shares of the company, Fibroscan is the ES has the Invention patent products, in February 2007, Nemonfory Pharmaceutical and es Company signed the "distribution Agreement", September 2009, Nemonfory Pharmaceutical and France es Company signed the Supplemental agreement of the Distribution agreement, the agreement agreed,　　ES Company authorized Nemonfory Pharmaceutical for China (excluding Hong Kong and Taiwan) Fibroscan Medical Equipment exclusive distributor, distribution period until September 2012. Since 2007, the shares in 302 hospitals, Guangzhou Southern Hospital and other 7 test centers for 600 patients with fibroscan detection and liver puncture detection control test. The results showed that noninvasive diagnosis of ultrasonic diagnostic instrument and liver puncture test were compared, Fibroscan can accurately detect the degree of liver fibrosis, and the higher the degree of liver fibrosis, the higher the accuracy.　　Therefore, the company plans to add Fibroscan to 100 hospitals in 2010 and 2011. The shares at that time said that in the Nemonfory pharmaceutical and ES Company signed the contract, did not determine the future permanent exclusive distribution rights, the company also did not master the patented technology, the existence of ES company in the future to change the distribution of the right to grant the possibility, resulting in fibroscan market competition. The Company intends to strengthen cooperation with ES company in the future, establish close business partnership, lay the foundation for long-term cooperation.